Interestingly, results from the TRITON2 study (NCT02952534) showed clinical activity of rucaparib was greater in castrate-resistant prostate cancer patients with BRCA2 mutations compared to BRCA1 mutations [40]. This evidence concerns the gene BRCA2 and prostate carcinoma.